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The two isomeric 20(22)-olefins and the four isomeric 20,22-epoxides of cholesterol have been 
examined as possible intermediates in the conversion of cholesterol to pregnenolone both by crude 
extracts of acetone-dried bovine adrenal cortex mitochondria, and by a partially purified cytochrome 
P-450 specific for the side chain cleavage ( P - 4 5 0 ~ ~ ~ ) .  The quantities of pregnenolone (measured by 
radioimmunoassay) formed from these putative intermediates and from cholesterol, (2057-20- 
hydroxycholesterol, (22R)-22-hydroxycholesterol, and (20R,22R)-20,22-dihydroxycholesterol have 
been compared. In both crude and purified systems, the conversion of the monohydroxycholesterols 
is somewhat more rapid than that of cholesterol. However, the dihydroxycholesterol is a very much 
more efficient precursor of pregnenolone. Whereas small amounts of pregnenolone were formed 
from the four 20,22-epoxycholesteroIs, and slightly larger amounts from the two 20(22)-didehydro- 
cholesterols in the crude enzyme systems, almost no conversion of these six compounds was 
observed with the purified system containing cytochrome P-45Oscc, adrenodoxin, adrenodoxin re- 
ductase, and an NADPH-generating system. It is concluded that the olefins and epoxides are not 
obligatory intermediates in the conversion of cholesterol to pregnenolone, and the conversions of 
cholesterol olefins and epoxides observed by us and by others may reflect the presence of extraneous 
enzymes such as double bond reductases and epoxide hydratases which are unrelated to pregnenolone 
biosynthesis. The relative effectiveness of the cholesterol olefins and epoxides, as well as 20-isocho- 
lesterol in inhibiting the formation of pregnenolone from [4-14C]cholesterol has been determined. 
The compounds which have the same configuration as cholesterol at C-20 are more potent inhibitors 
of this conversion than the olefins in which the C-21, C-20, C-22, C-23 carbon system is planar, 
or than those compounds which have the opposite configuration to cholesterol at C-20 (i.e. 20- 
isocholesterol, (20S,22S)-20,22-epoxycholesterol and (20S,22R)-20,22-epoxycholesterol). The enzyme 
appears to be more fastidious in its steric requirement at C-20 than at C-22. Since the olefins and 
epoxides are stereochemically rigidified around the C-20 to C-22 bond, these inhibitor studies suggest 
that the natural conformation of cholesterol on the side chain cleavage enzyme system is such that 
the side chain is fully extended and thus closely resembles the conformation of cholesterol in the 
crystal state. 
Presented in preliminary form at the 174th American Chemical 
Society National Meeting, Chicago, Illinois, U.S.A., August 29- 
September 1, 1977. Division of Biological Chemistry, Abstract 
BIOL 47. ano-4,4,17~-trimethylandrost-5-en-17~-ol-3-one. 
Abbreviations. The following abbreviations are used : cyto- 
chrome P-45OSCC, a highly purified bovine adrenal cortex mitochon- 
drial cytochrome P-450 that cleaves the side chain of cholesterol 
to pregnenolone and is inactive in the 11 P-hydroxylation reaction; 
pregnenolone, 3a-hydroxypregn-5-en-20-one; cyanoketone, 2cc-cy- 
Enzymes. Adrenodoxin reductase (EC 1.6.7.1); glucose-6-phos- 
phate dehydrogenase (EC 1 .I .  1.49). 
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Cleavage of the C-20 to C-22 bond of cholesterol 
(compound I)’ to pregnenolone (compound 11) is an 
essential step in the biosynthesis of steroid hormones. 
This reaction requires three proteins obtainable from 
the adrenal cortex: an iron sulfur protein known as 
adrenodoxin or adrenal ferrodoxin, the flavoprotein 
adrenodoxin reductase, and the cytochrome P-450 
specific for side chain cleavage ( P - 4 5 0 ~ ~ ~ ) ,  as well as 
an NADPH-generating system [l]. Three molecules 
each of oxygen and of NADPH are consumed in the 
conversion of one molecule of cholesterol to pregneno- 
lone and isocaproaldehyde (4-methylhexanal) either 
by highly purified enzyme preparations [2] or by crude 
adrenal mitochondria [3]. Despite substantial pro- 
gress in our understanding of the enzymology of 
this reaction, its fundamental details remain contro- 
versial. 
Several mechanisms of the side chain cleavage 
are currently in vogue. The now ‘classical’ sequential 
hydroxylation mechanism [4] holds that cholesterol 
first undergoes hydroxylation to (20S)-20-hydroxy- 
cholesterol (compound IX) or (22R)-22-hydroxycho- 
lesterol (compound X), which are then converted to 
(20R,22R)-20,22-dihydroxycholesterol (compound 
XI), and the latter is in turn cleaved to pregnenolone 
and isocaproaldehyde. Extensive efforts to support 
or refute this mechanism by kinetic measurements 
have been inconclusive [5 - 81. The enzymatic forma- 
tion of both (22R)-22-hydroxycholesterol (compound 
X) and (20R,22R)-20,22-dihydroxycholesterol (com- 
pound XI) is firmly established [9], and the turnover 
of these compounds as sequential substrates and prod- 
ucts has been demonstrated by means of ‘*O isotope 
techniques [8]. 
Lieberman and co-workers [lo, 111 have shown that 
analogues of cholesterol in which the C-22 to C-27 
moiety of the side chain has been replaced by a tert- 
butyl or a p-tolyl group (and consequently incapable 
of being oxygenated at the carbon atom corresponding 
to C-22 of cholesterol) are hydroxylated at C-20 and 
converted to pregnenolone by adrenal mitochondria. 
Thus, these workers have suggested that the true inter- 
mediates are transient reactive species (ionic, free 
radical, or of a hybrid type) and that the hydroxylated 
cholesterol derivatives are side products. With highly 
purified side-chain cleavage enzyme preparations, 
however, Morisaki et al. [12] were unable to detect 
any conversion of (20R)-20-p-tolylpregn-5-ene-3P,20- 
diol to pregnenolone. This compound was erroneously 
assigned the (20S)-chirality by Morisaki et al. [12]. 
Recently, Kraaipoel and co-workers [3,13,14] 
observed that 20(22)-didehydrocholesterol (compound 
111 or IV, unspecified stereochemistry) markedly 
All steroid structures and their designation by Roman numer- 
als are given in Fig. 1. The systematic names for these compounds 
will be found in Tables 1 and 2. 
stimulates the oxygen consumption of respiring mito- 
chondria, and increased the formation of pregneno- 
lone. They proposed an olefin-epoxide mechanism 
which is analogous in some ways to the olefin-epoxide 
intermediates in the dealkylation of fucosterol in 
insects [15]. The mechanism of Kraaipoel et al. 
[3,13,14] requires the existence of enzymes capable 
of converting cholesterol to a 20(22)-didehydrocho- 
lesterol, epoxidizing the 20(22) double bond, and an 
epoxide hydratase forming the (20R,22R)-20,22-di- 
hydroxycholesterol. Circumstantial evidence for the 
existence of an epoxide intermediate has been provided 
[3,13,14]. In the pathway proposed by Kraaipoel 
et al. the (20,S)-20-hydroxycholesterol and (22l9-22- 
hydroxycholesterol are regarded as side products 
resulting from the hydration (presumably, by addi- 
tional enzymes) of the 20(22)-olefin(s). 
In preliminary studies employing gas chromatog- 
raphy-mass spectrometry, Morisaki et al. [ 161 were 
unable to detect significant conversion of any of the 
four isomeric 20,22-epoxycholesterols (compounds 
V - VIII) or of E-20(22)-didehydrocholesterol (com- 
pound I l l )  to pregnenolone by a highly purified side- 
chain cleavage enzyme system. Moreover, these puta- 
tive intermediates did not trap any radioactivity from 
[3H]cholesterol in the enzyme systems that produced 
pregnenolone. Using gas chromatography-mass spec- 
trometric techniques, Burstein and co-workers [17] 
were likewise unable to detect significant conversion 
of E-20(22)-didehydrocholesterol (compound III), Z- 
20(22)-didehydrocholesterol (compound IV), or (20R, 
22R)-20,22-epoxycholesterol (compound V) to preg- 
nenolone in crude adrenal mitochondria1 acetone 
powders. These authors did, however, find that (20R, 
22S)-20,22-epoxycholesterol (compound VII) was 
converted to pregnenolone with 20 % of the efficiency 
of cholesterol. The findings of Kraaipoel et al. [3,13, 
141 cannot easily be reconciled with those of Morisaki 
et al. [16] and of Burstein et al. [17], although the 
purity and manner of preparation of the side-chain 
cleavage enzyme systems used by these three groups 
were quite different. 
In the light of these conflicting views on the mech- 
anism of the enzymatic conversion of cholesterol to 
pregnenolone, we have undertaken a systematic and 
detailed examination of the possible conversion of 
the E and the Z 20(22)-didehydrocholesterols (com- 
pounds Ill and IV) and of the four isomeric 20,22- 
epoxycholesterols (compounds V - VIII) to pregnen- 
olone. These experiments have been conducted in 
parallel with crude extracts of acetone-dried bovine 
adrenal mitochondria and with the refined enzymes 
obtained from this source by Shikita and Hall [ l] .  
Moreover, we have used highly sensitive, specific and 
quantitative radioimmunoassay procedures for mea- 
suring pregnenolone, thus obviating the necessity for 
uncertain corrections for yields entailed in chroma- 
B. A. Teicher, N. Koizumi, M. Koreeda, M. Shikita, and P. Talalay 13 
tographic and gas chromatographic-mass spectro- 
metric procedures employed by other workers. The 
proposed intermediates have all been synthesized in 
our laboratories by independent stereoselective proce- 
dures and have been unambiguously characterized 
[18,19]. Our syntheses differ from those of other in- 
vestigators [20,21]. The present paper constitutes the 
full description of our findings which have already 
been communicated in preliminary form [22]. 
As will be shown, the purified adrenal enzyme 
system fails to promote significant conversion of any 
of the cholesterol olefins or epoxides to pregnenolone, 
and consequently, we were able to obtain measure- 
ments of the inhibitory activities of these compounds 
on the conversion of cholesterol to pregnenolone. 
Since the olefin and epoxide functions impart a signif- 
icant measure of conformational rigidity to the side 
chain, these inhibitor studies have led to inferences 
regarding the preferred conformation of the side 
chain at the active site of the cholesterol degrading 
enzyme. 
MATERIALS AND METHODS 
Muter i d s  
All solutions were prepared from reagent grade 
chemicals in deionized, glass-distilled water. The 
antisera to pregnenolone 3-hemisuccinate coupled to 
human serum albumin were obtained from Radio- 
assay Systems Laboratories (Carson, Calif.). [7-3H]- 
Pregnenolone (specific activity 20 Ci/mmol) and [4- 
''C]cholesterol (specific activity 55.5 Ci/mol) were 
purchased from New England Nuclear (Albany, MA.). 
The liquid scintillation fluor, known as PCS, was ob- 
tained from Amersham (Arlington Heights, Ill.). Crys- 
talline yeast glucose-6-phosphate dehydrogenase was 
supplied by Sigma Chemical Company (St Louis, 
Mo.). Crystallized bovine plasma albumin was ob- 
tained from Armour Pharmaceutical Company (Chi- 
cago, Ill.). The E and 2 isomers of 20(22)-didehydro- 
cholesterol, the four isomers of 20,22-epoxycholester- 
01, and (20R,22R)-20,22-dihydroxycholesterol were 
synthesized in our laboratories [18,19]. Samples of 
(20S)-20-hydroxycholesterol and (22R)-22-hydroxy- 
cholesterol were prepared by established procedures 
[23,24]. 20-Isocholesterol was prepared by a novel 
stereospecific method [25]. The cyanoketone inhibitor 
used to retard the oxidation of pregnenolone to pro- 
gesterone [26,26a] was synthesized according to Man- 
son et al. [27]. 
Protein Deferminations 
The method of Lowry et al. [28] was used with 
crystalline bovine plasma albumin as standard. 
Preparation of Crude Side-Chain Cleavage Enzyme 
from Bovine Adrenal Cortex Mitochondria 
Acetone-dried powders of bovine adrenal mito- 
chondria prepared according to standard procedures 
[5,28], were stable for many months when stored in a 
vacuum desiccator over Pz05 at - 20 "C. For each 
experiment, the acetone powder (10 mg) was homo- 
genized by hand in a tight-fitting all-glass tissue grinder 
in 2.0 ml of 20 mM potassium phosphate buffer, 
pH 7.8, containing 1 mM magnesium sulfate. The 
homogenate was centrifuged at 20000 x g (average) 
for 30 min. Aliquots of the resulting straw-colored 
supernatant were used as the side-chain cleavage en- 
zyme. These preparations (protein concentration 
0.35 -0.55 mg/ml) retained enzymatic activity for 
several weeks when stored at - 80 "C. 
Adrenal Activator Preparation 
Adrenal activator was obtained by homogenizing 
the acetone powder (10 mg/ml) in 20 mM potassium 
phosphate, pH 7.8, 1 mM magnesium sulfate, heating 
the preparations for 2 min at 100 "C, and centrifuging 
at 20000 x g (average) for 30 min. The supernatant 
fractions (protein concentration 0.76 - 1.25 mg/ml) 
served as activator [29- 311. 
Purgied Side-Chain Cleavage Enzyme 
Side-chain cleavage cytochrome P-450 was pre- 
pared as described [1,32]. The cytochrome P-450 
concentrations in the preparation used for these ex- 
periments was 36 nmol/ml, as determined by CO 
difference spectra [33], and the protein concentration 
was 9.0 mg/ml. The preparation was stored at - 20 "C 
in 50 % glycerol. Adrenodoxin and adrenodoxin re- 
ductase were prepared by described methods [34,35]. 
Incubation Conditions 
The compositions of the incubation mixtures for 
the measurement of the formation of pregnenolone 
from cholesterol and other precursors are given with 
the individual protocols (see Fig. 2, Tables 1 and 2). 
Analysis o j  Reaction Products 
The enzymatic reactions were stopped by the addi- 
tion of 2 ml of cyclohexane, mixed on a Vortex mixer 
for 1 min, and agitated for 30 min on a mechanical 
shaker. The organic solvent layer (centrifuged if 
necessary) was transferred to acid-washed 12 x 75-mm 
glass tubes, and the cyclohexane was evaporated on a 
vacuum centrifuge [36]. The aqueous residue was ex- 
tracted with a second portion (2 ml) of cyclohexane, 
the extracts were combined and evaporated on the 
vacuum centrifuge. The dry residues were stored at 
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4 "C until immediately before radioimmunoassay, or 
for incubations with [4-14C]cholesterol until analysis 
by thin-layer chromatography. In the latter case, the 
residues were dissolved in 50 yl of methanol and ap- 
plied to 2-cm wide channels on silica gel chromato- 
gram sheets (20 x 20 cm; Eastman Kodak). The chro- 
matograms were developed twice with heptane/di- 
ethyl ether/glacial acetic acid (60/40/2, by vol.). The 
spots corresponding to cholesterol and pregnenolone 
were visualized by autoradiography, and then cut 
out and counted in 10 ml of a toluene-based scintilla- 
tor. The efficiency was 96 %. 
Radioimmunoassay of Pregnenolone 
Pregnenolone was measured by radioimmunoassay 
with slight modifications of described procedures [37 - 
401. The residues obtained by organic solvent extrac- 
tion of incubation mixtures were dissolved in 20 p1 of 
methanol and diluted with 2 ml of steroid assay 
buffer [85 mM potassium phosphate buffer, pH 7.0, 
containing 0.15 M sodium azide, 0.15 M sodium 
chloride, and 1 % (w/v) gelatin]. Appropriate aliquots 
(in duplicate) of these mixtures were diluted to 0.5 ml 
with steroid assay buffer. To these tubes was added 
0.2 ml of the antigen-antibody solution (10 yl of the 
concentrated pregnenolone antiserum and 0.18 pg 
of purified [7-3H]pregnenolone [41,42] in 20 y1 of 
methanol diluted to a final volume of 20 ml with steroid 
assay buffer). After equilibration for 90 min at room 
temperature, the tubes were placed in an ice bath 
for 10 min, 0.2 ml of cold dextran-coated charcoal 
suspension (625 mg of activated Norit-A and 62.5 mg 
of Dextran T-70 suspended in 100 ml of steroid assay 
buffer) was then added, and the tubes were mixed for 
1 min. After a further 20 min, the charcoal was sedi- 
mented by centrifugation, and aliquots (0.4 ml) of 
the supernatants were transferred to scintillation 
vials and counted to ? 1.5% error in the presence 
of 10 ml of PCS scintillator. The standard curve for the 
pregnenolone radioimmunoassay was linear from 
0.05 ng (0.158 pmol) to 5 ng (15.8 pmol). None of 
the cholesterol derivatives used in this study showed 
any reactivity with the pregnenolone antiserum, and 
did not interfere with the measurement of small 
amounts of pregnenolone. The survival of pregneno- 
lone in the incubation systems was examined by in- 
cubating known amounts of pregnenolone under 
assay conditions. Recoveries were essentially quanti- 
tative. Comparison of the amounts of pregnenolone 
formed from [4-'4C]cholesterol by radioactive mea- 
surements and by radioimmunoassay showed satis- 
factory agreement. Thus, in one experimental series, 
wherein the concentration of [4-14C]cholesterol was 
2.5 pM (0.5 nmol in a 200-p1 incubation system) the 
amount of pregnenolone formed was 28 7pmol 
(eight determinations) by radioimmunoassay and 
31 k 10 pmol (four determinations) by radioactivity 
measurements. 
RESULTS AND DISCUSSION 
Formution of Pregnenolone from Cholesterol 
and Various Didehydro, Epoxy, 
and Hydroxy Derivatives of Cholesterol 
The initial evaluation of these compounds as pre- 
cursors of pregnenolone was carried out with crude 
centrifuged extracts of acetone-dried bovine adrenal 
mitochondria supplemented with a soluble heat- 
stable activator (obtained from similar extracts) and 
an NADPH-generating system. Table 1 presents the 
mean quantities of pregnenolone (measured by radio- 
immunoassay) formed from the various steroids in 
four separate experiments. The values have been 
normalized for each experiment in relation to the 
amount of pregnenolone formed from cholesterol 
(100). Although the results obtained at only a single 
low concentration of steroid (2.5 yM, or about one- 
tenth of the K ,  value) are shown in Table 1, the 
relative rates of conversion were comparable at 5.0 
and 12.5 yM concentrations of each steroid. Low 
concentrations of test compounds were selected to 
minimize the problems of steroid solubility, and this 
proved feasible because of the high sensitivity of the 
radioimmunoassay. Under these conditions, the two 
monohydroxylated derivatives of cholesterol are be- 
tween 1.5 and 2 times more efficient precursors of 
pregnenolone than cholesterol itself, whereas (20R, 
22R)-20,22-dihydroxycholesterol is converted to preg- 
nenolone much more efficiently (6.7 times) than 
cholesterol, in agreement with the findings of other 
workers. There are also several reports on the con- 
version of the monohydroxycholesterols to pregnen- 
olone, although the reported rates of these conver- 
sions vary considerably [6,8]. 
In contrast, the two isomeric 20(22)-didehydro- 
cholesterols and the four isomeric 20,22-epoxycho- 
lesterols gave rise to only between 15.8 and 66.2% 
of the amount of pregnenolone formed from cho- 
lesterol itself (Table 1). Although we conclude that 
the olefins and epoxides are not likely to be true inter- 
mediates in the biosynthesis of pregnenolone from 
cholesterol, the quantities of pregnenolone formed 
from these oxygenated species is not negligible, and 
these amounts increased with time, the amount of 
enzyme, and steroid concentrations (over a limited 
range). Moreover, the didehydrocholesterols and 
epoxycholesterols neither react nor interfere with the 
pregnenolone radioimmunoassay. The slow conver- 
sion of the dehydrocholesterols and epoxycholesterols 
to pregnenolone in these relatively crude enzyme sys- 
tems could be attributed to the presence of ancillary 
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Table 1.  Convwsion of cholestrrol and various 20(22/-didehydro, 
20,22-q10.~~, und 2o-/?j'C/Yo.wJ. OY 22-hyclroxy cholesterol analogurs 
to pregnmolonr. /iy (.rude rx trac ts  rlf'ucetone powsders of bovine adrenul 
c ' o r f i ~ . ~  mitoc~l7onrlriu 
The reaction systems contained in a final volume of 200 P I :  20 m M  
ium phosphate, pH 7.8; 0.1 Y; (wiv) bovine serum albumin; 
5 mM reduced glutathione; 0.5 m M  magnesium sulfidte; 0.003'j; 
(v,v) Triton N-101; 6 pM cyanoketone in 0.1 p1 of dimethylform- 
amide; 2.5 p M  (500 pniol) cholesterol or analogue in 5 1.11 of meth- 
anol; 25 pI of crude side-chain cleavage enzyme, and 100 pl of ac- 
tivator solution. After a preliminary incubation of 20 min at 37 "C 
with gentle agitation, the reaction wab initiated by addition of an 
NADPWgeiierating system composed of the following ingredienls 
and giving the final concentrations: 5 niM glucose 6-phosphate; 
0.2 mM NADP' ; crystalline yeast glucose-6-phosphate dehydro- 
genase (0.26 pg); and 5 m M  magnesium chloride. Reaction mix- 
tures were incubated for 60 min at  37 "C with gentle agitation. 
The reaction mixture was extracted with cyclohexane and the preg- 
nenolone was analyzed on aliquots of the extracts by rddioimmuno- 
assay, as  described under Methods. The results are expressed as 
the means ( f S.E.M.)  of four separate experiments, conducted 
with different enzyme preparations. The mean quantity ofpregneno- 
lone formed in the four experiments was 28.0 6.9 pmol (range 
11 .5 - 69.5 pmol). The amount of pregnenolone formed from cho- 
lesterol in the four experiments has been normalized to 100. Incuba- 
tion reaction mixtures to which no  exogenous steroid was added 
contained less than 3 pmol of pregnenolone. The values given in 
this table have been corrected for the endogenous pregnenolone 
Steroid added Relative amounts 
of pregnenolone 
formed 
Cholesterol ( I )  100 
I<-20(22)-Didehydrocholesterol (1 I I )  65.2 i 7.9 
Z-20(22)-Didehydrocholesterol (IV) 66.2 i 12.3 
(20S,22S)-20,22-Epoxycholesterol ( V I )  26.4 6.5 
(20S,22R)-20.22-Epoxycholesterol (VI 11) 15.8 6.1 
(20R,22S)-20,22-Epoxyclioleste~ol (V11) 25.8 8.6 
(20R,22R)-20,22-Epoxycholesterol (V) 34.1 i 6.4 
(20S)-20-Hydroxyctiolesterol (IX) 154.8 & 12.6 
(2212)-22-Hydroxychcilesterol (X) 182.4 2 32.4 
(20R,22K)-20,22-Dihydroxycholesterol (XI) 671.8 f 68.3 
enzymes that might cleave the epoxides (compounds 
V - V I l I )  to diols (some of which might then enter 
the sequential hydroxylation pathway), or might 
reduce the 20,22 double bond of the olefins (com- 
pounds 111, 1V) to cholesterol. 
The results were much more clear-cut when the 
same compounds were subjected to the action of the 
purified side-chain cleavage enzyme system, consisting 
of bovine adrenal cytochroine P-450scc, adrenodoxin, 
adrenodoxin reductase, and an NADPH-generating 
system (Fig. 2). At three concentrations of steroid 
(2.5, 7.5, and 15 pM), there was very little conversion 
of any of the four epoxides o r  of either of the two 
isomeric olefins to pregnenolone, and the small amount 
of pregnenolone formed from these compounds did 
not rise with increasing steroid concentration. The 
actual quantities of endogenous pregnenolone de- 
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Fig. 1 . Slruc,furr.c. 0/ stcwiids arid 1hc.ir designations I ~ J  Rotnan 
nurncds .  Systematic names are given in Tables 1 and 2 
rates of formation of pregnenolone from the two ino- 
nohydroxycholesterols and the dihydroxycholesterol 
are in the same relative order as with the crude sys- 
tem (cf. Fig. 2 and Table 1). At low substrate concen- 
trations, the amount of pregnenolone formed from the 
epoxycholesterols or didehydrocholesterols is a larger 
fraction of that formed from cholesterol, whereas at 
the higher substrate concentrations, the yield is negli- 
gible, amounting to  no more than 15 of the product 
formed from cholesterol or 4 %  of that formed from 
equimolar concentrations of (20R,22R)-20,22-dihy- 
droxycholesterol. Although the significance of the 
apparent formation of very small quantities of preg- 
nenolone from the olefins and epoxides in the crude 
enzyme system is not clear, the conversion of these 
compounds becomes negligible as the enzyme system 
is purified and consequently, these compounds cannot 
be obligatory intermediates in the formation of preg- 
nenolone from cholesterol. Our findings are in agree- 
ment with those of Morisaki et al. [16] and Burstein 
and Gut [S]. Wang and Kimura [43] have independent- 
ly concluded that the participation of an epoxide 
hydratase in the cholesterol side-chain cleavage reac- 
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Fig. 2. Formation of pregnenolone as a ,function of subsirate concen- 
tration by highly purified cytochrome P450scc f rom dxferent suh- 
strates. Formation from cholesterol (E--m); (20S)-20-hydroxy- 
cholesterol (A-A) ; (22R)-22-hydroxycholesterol (v-v); 
(20R,22R)-20,22-dihydroxycholesterol (+a); (203,22S)-20,22- 
epoxycholesterol (0 . . . . . 0) ; (20R,22R)-20,22-epoxycholesterol 
(t. . .); (20R,22S)-20,22-epoxycholesterol([1--0) ; (20S,22R)- 
20,22-epoxycholesterol (A-A); E-20(22)-didehydrocholesteroi 
(*---a); and Z-20(22)-didehydrocholesterol (A - . -A). The 
incubation system contained in a final volume of 200 pl: 50 mM 
potassium phosphate, pH 7.0; 5 mM L-cysteine; 1 mM EDTA; 
the indicated concentration of each steroid in 2.5 p1 of methanol; 
18 pg (72 pmol) of purified cytochrome p - 4 5 0 ~ ~ ~ ;  21 pg of highly 
purified adrenodoxin; and 7.5 pg of highly purified adrenodoxin 
reductase, as well as an NADPH-generating system to give the 
following final concentrations: 5 mM glucose 6-phosphate, 0.2 mM 
NADP+, crystalline yeast glucose-6-phosphate dehydrogenase 
(0.26 pg), and 2.5 mM magnesium chloride. Mixtures were incu- 
bated at 37 "C for 60 min with gentle agitation. The incubation 
mixture was extracted with cyclohexane, and pregnenolone was 
determined in an aliquot of the extract by radioimmunoassay (see 
Methods). Incubation mixtures to which no steroids were added 
contained 0.081 0.039 nmol of pregnenolone 
tion is unlikely. Moreover, the purified enzyme prepa- 
rations used in these studies [l] do not appear to 
contain epoxide hydratase activity. Our results do not 
support the mechanism of Kraaipoel et al. [3,13,14] 
who do not give quantitative information on the rela- 
tive efficiency of the conversion of their 20(22)-di- 
dehydrocholesterol (of unspecified stereochemistry) 
to pregenenolone, and consequently their experiments 
cannot be assessed fully. The transient putative epox- 
ide intermediate detected on thin-layer chromatog- 
raphy [13] was claimed by these workers to be con- 
verted to (20R,22R)-20,22-dihydroxycholesterol upon 
treatment with perchloric acid. However, as already 
pointed out by Morisaki et al. [I61 the chromato- 
graphic mobility of this compound is inappropriate for 
any of the 20,22-epoxides of cholesterol. The mech- 
anism of Kraaipoel must therefore be rejected. 
If (20R,22R)-20,22-dihydroxycholesterol is con- 
sidered an obligatory intermediate, the manner of 
its formation by an epoxide hydratase from the 
20,22-epoxycholesterols is governed by certain steric 
limitations. The (20S,22S)-20,22-epoxycholesterol is 
not capable of yielding (20R,22R)-20,22-dihydroxy- 
cholesterol by any chemically plausible mechanisms. 
The formation of the diol from the (20R,22R)- 
epoxide requires enzymatic cis hydration which ap- 
pears to be rare [44] and has not been observed in 
animal tissues (which normally carry out specific 
trans hydrations). The two remaining epoxide isomers 
could yield the (20R,22 R)-20,22-dihydroxycholesterol 
by trans hydration. The preferred enzymatic ring 
opening would involve attack at the least substituted 
carbon atom [45], which in the case of the 20,22- 
epoxycholesterols is C-22, and leads to the prediction 
that the preferred epoxide substrate should have been 
(20R,22S)-20,22-epoxycholesterol. Nevertheless, the 
efficiency of all of the four epoxides as precursors of 
pregnenolone in crude enzymatic systems (Table 1) 
is low and does not vary with stereochemistry. 
Effects of Various ZO(22)-Didehydro, 20,22-Epoxy, 
und 20-Hydroxy or 22-Hydroxy Cholesterol Analogues 
on the Conversion of Cholesterol to Pregnenolone 
The effects of two concentrations (2.5 and 12.5 pM) 
of the various 20(22)-didehydrocholesterols and 20,22- 
epoxycholesterols on the conversion of [4-'4C]cho- 
lesterol (1.75 pM) to pregnenolone by purified side- 
chain cleavage enzyme are shown in Table 2. These ex- 
periments were feasible since none of the compounds 
appear to be substrates for this enzyme. Because con- 
formational restrictions rigidly define the relative 
spatial disposition of C-17, C-20, C-21, C-22, and C-23 
in these compounds, their inhibitory potency may in- 
dicate the conformation of cholesterol and its hydrox- 
ylated derivatives at the active site of the side-chain 
cleavage enzyme. Although complete studies of in- 
hibitory constants have not been undertaken, Table 2 
indicates the relative potency of the various inhibitors, 
and the approximate concentrations (15" values) re- 
quired to obtain 50 % inhibition. The stereochemical 
configurations at both C-20 and C-22 are important 
for binding to the side-chain cleavage enzyme, al- 
though the former is somewhat more critical than 
the latter. This finding is entirely consistent with the 
conclusions of Morisaki et al. [12] on the stereochem- 
ical specificity at C-20 and C-22 of hydroxylated 
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cholesterols in this enzymatic system. Both the E 
and Z olefins in which the C-21 methyl group lies 
rigidly in the same plane as the side chain extending 
from C-23 compete only poorly with cholesterol for 
the active site(s) of the cleavage enzyme, as seen in 
projection structures. 
The chirality of the configurations at C-20 of 20- 
isocholesterol, (20S,22S)-20,22-epoxycholesterol, and 
(20S,22R)-20,22-epoxycholesterol is opposite to that 
of cholesterol. 
20-Isocholesterol 
The (20R,22R)-20,22-epoxycholesterol is a more 
potent inhibitor than (20R,22S)-20,22-epoxycholester- 
ol suggesting again that the enzyme is more fastid- 
ious in its stereochemical requirements at C-20 than 
at C-22, and establishing that the preferred conforma- 
tion of C-17, C-20, C-22, and C-23 of the cholesterol 
side chain on the cleavage enzyme is maximally ex- 
tended. This conformation of the side chain is very 
similar to that of crystalline cholesterol (anhydrous 
and monohydrate) in which the C-22 to C-23 bond 
points away from the ring system [46-491. For 
(20R,22R)-20,22-epoxycholesterol, the three-mem- 
bered epoxide ring also rigidly constrains the side 
chain segment comprising C-22 and C-23 to assume a 
conformation trans to the ring system. The side chain 
is similarly disposed in (20R,22R)-20,22-dihydroxy- 
cholesterol, if the assumption is made that the two 
hydroxyl groups both occupy positions analogous 







I t  is not surprising that these compounds are much 
poorer inhibitors of the side-chain cleavage enzyme 
than (20R,22S)-20,22-epoxycholesterol and (20R,22R)- 
20,22-epoxycholesterol, both of which have the same 




It is not surprising that the most effectively bound 
epoxide is not a substrate, since (20R,22R)-20,22- 
epoxycholesterol cannot give rise to (20R,22R)-20,22- 
dihydroxycholesterol by trans hydration, which ap- 
pears to be by far the most common mechanism for 
epoxide opening in biological systems. 
The effects of adding (20S)-20-hydroxycholesterol, 
(22R)-22-hydroxycholesterol, and (20R,22R)-20,22-di- 
hydroxycholesterol to  the highly purified enzyme 
system converting [4-’4C]cholesterol to pregnenolone 
are also shown in Table 2. Since these compounds are 
all substrates of the reaction, the apparent inhibitions 
undoubtedly reflect complex events including isotope 
dilution of intermediates. The results indicate that 
these compounds have access to  the active site of the 
enzyme, and offer some measure of their ability to 
suppress formation of pregnenolone from added [4- 
‘4C]cholesterol. 
Biosynthesis of Pregnenolone from Cholesterol 
Table 2. Effect o j  vurious didehydro, epoxy, and hydroxy cholesterol 
derivatives on the conversion oj"4-'4C]cholesteroI to pregnenolone 
The incubation system contained in a final volume of 200 pl: 2.25 pg 
(9 pmol) of, purified cytochrome P-45OScc, 21 pg of adrenodoxin, 
and 7.5 pg of adrenodoxin reductase; 50 mM potassium phosphate, 
pH 7.0; 5 mM L-cysteine; 1 mM EDTA; 1.75 pM [4-'4C]cho- 
lesterol, and 2.5 or 12.5 pM of the other steroid in a total of 5 pl 
of methanol. The reaction was started by addition of the NADPH- 
generating system which gave a final concentration of: 5 mM glu- 
cose 6-phosphate, 0.25 m M  NADP', 2.5 niM magnesium chloride, 
and 0.26 pg (1.5 units) of crystalline yeast glucose-6-phosphate 
dehydrogenase. The reaction mixtures were incubated for 15 min 
at 37 "C,  the mixtures extracted once with 2 ml of cyclohexane and 
once with 2 ml of ethyl acetate, and the products were separated on 
a silica gel chromatogram sheet (see Methods). The regions corre- 
sponding to pregnenolone were counted. In the control vessels, in 
the absence of inhibitors, 52 f 9 pmol of cholesterol were converted 
to pregnenolone. This value has been set at 100 
Steroid added Relative Apparent 
quantities I5 0 
of [14C]pregnen- 
olone formed 
in the presence 
of inhibitors or 
intermediates at 
2.5 pM 12.5 pM 
None 
PM 













- (111) 76 76 
(IV) 79 72 - 
P I )  100 63 20 
(VIII) 74 59 15 
(VW 92 36 7.5 
(V) 60 31 5 
(IX) 89 32 7.0 
(XI 61 52 14.5 
lesterol (XI) 100 43 10.0 
The relatively weak inhibitory power of the 20(22)- 
olefins of cholesterol (Table 2) is in agreement with 
the findings of Morisaki et al. [16]. However, in con- 
trast, we observed that the (20R,22S)-20,22-epoxy- 
cholesterols and the (20R,22R)-20,22-epoxycholester- 
01s are more potent inhibitors than the correspond- 
ing diastereomeric epoxides. Although these conflict- 
ing results were both obtained with highly purified 
enzymes, the experimental conditions differed in 
several respects. Burstein et al. [50] have studied the 
effects of many cholesterol analogues on the forma- 
tion of [14C]pregnenolone from ['4C]cholesterol in 
crude adrenal mitochondria1 acetone powder extracts. 
Since an indeterminate number of the compounds 
tested by Burstein et al. [50] were also substrates, it 
is somewhat difficult to interpret their findings con- 
clusively. Nevertheless, these authors found 20-iso- 
cholesterol to be a considerably more potent inhibitor 
of the enzymatic process than is indicated by our ex- 
perimen ts. 
These studies were supported by Grants AI-12150 (M.K.) and 
AM-07422 (P.T.) from the National Institutes of Health. We wish 
to express our appreciation to Dr Peter F. Hall for information on 
the radioimmunoassay of pregnenolone. 
REFERENCES 
1. Shikita, M.&Hall, P. F. (1973)J. Biol. Chem. 248,5598-5604. 
2. Shikita, M. & Hall, P. F. (1974) Proc. Narl Acud. Sci. U.S.A.  
71, 1441 - 1445. 
3. Krdaipoel, R. J., Degenhart, H. J . ,  Leferink, J. G., van Beek, 
V., de Leeuw-Boon, H. & Visser, H. K. A. (1975) FEBS 
4. Shimizu, K., Gut, M. & Dorfman, R. I .  (1962) J .  Biol. Chcm. 
5. Burstein, S .  & Gut, M. (1969) Steroids, 14, 207-217. 
6. Burstein, S., Kimball, H. & Gut, M. (1970) Steroids, 15, 809- 
857. 
7. Burstein, S., Dinh, J., Co, N., Gut, M., Schleyer, H., Cooper, 
D. Y. & Rosenthal, 0. (1972) Biochemistry, 11, 2883-2891. 
8. Burstein, S. & Gut, M. (1976) Steroids, 28, 115-131. 
9. Burstein, S., Zamoscianyk, H., Kimball, H. L., Chaudhuri, N. 
K. &Gut ,  M. (1970) Steroids, 15, 13-60. 
10. Luttrell, B., Hochberg, R. B., Dixon, W. R., McDonald, P. D. 
& Lieberman, S. (1972) J .  Biol. Chem. 247, 1462- 1472. 
11. Hochberg, R. B., McDonald, P. D., Feldman, M. & Lieber- 
man, S. (1974) J .  Biol. Chem. 249, 1277-1285. 
12. Morisaki, M., Sato, S., Ikekawa, N.  & Shikita, M. (1976) 
FEBS Lett. 72, 337 - 340. 
13. Krdaipoel, R. J., Degenhart, H. J., van Beek, V., de Leeuw- 
Boon, H., Abeln, G., Visser, H. K. A. & Leferink, J .  G. 
(1975) FEBS Leu. 54, 172-179. 
14. Kraaipoel, R. J., Degenhart, H. J.  & Leferink, J. G. (1975) 
FEBS Lett. 57, 294 - 300. 
15. Awata, N., Morisaki, M. & Ikekawa, N. (1975) Biochem. Bio- 
phys. Res. Commun. 64, 157- 161. 
16. Morisaki, M., Bannai, K., Ikekawa, N. & Shikita, M. (1976) 
Birichem. Biophys. Res. Commun. 69, 48 1 - 488. 
17. Burstein, S., Byon, C. Y., Kimball, H. L. & Gut, M. (1976) 
Steroids, 27, 691 -701. 
18. Koreeda, M., Koizumi, N. &Teicher, B. A. (1976) Tetrahedron 
Left .  4565 -4568. 
19. Koreeda, M., Koizumi, N. & Teicher, B. A. ( 1  976) J .  Clzem. 
Soc. Chem. Commun. 1035- 1036. 
20. Bannai, K., Morisaki, M. & Ikekawa. N. (1976) J .  Chem. Soc. 
Perkin Trans. 1, 2116-2120. 
21. Byon, C. Y .  & Gut, M. (1976) J .  Org. Chem. 41, 3716-3722. 
22. Teicher, B. A., Shikita, M., Koreeda, M. & Talalay, P. (1977) 
23. Sheikh, Y. M.  & Djerassi, C. (1973) J .  Org. Chem. 38, 3545- 
24. Burrows, E. P., Hornby, G. M.  & Caspi, E. (1969) J .  Org. 
Leii. 50, 204-209. 
237, 699 - 702. 
Abstr. 174th Am. Chem. Soc. Natl Meez. Biol. 47. 
3554. 
Chem. 34, 103 - 107. 
B. A. Teicher, N. Koizumi, M. Koreeda, M. Shikita, and P. Talalay 19 
25. Koreeda, M. & Koizumi, N. (1977) Abstr. 174th Am. Chem. 
26. Goldman, A. S. (1967) J .  Clin. Endocrinol. 27, 320-324, 325- 
26a. Goldman, A. S. (1968) J .  Clin. Endocrinol. 28, 1539-1546. 
27. Manson, A. J., Stonner, F. W., Neumann, H. C., Christian- 
sen, R. G., Clarke, R. L., Ackerman, J. H., Page, D. F., 
Dean, J. W., Phillips, D. K., Potts, G. O., Arnold, A, ,  Bey- 
ler, A. L. & Clinton, R. 0. (1963) J .  Med. Chem. 6, 1-9. 
28. Lowry, 0. H., Rosebrough, N. J.,  Farr, A. L. & Randall, R.  
J. (1951) J .  Bid.  Chem. 193, 265-275. 
29. Kan, K. W. & Ungar, F. (1973) J .  Biol. Chem. 248,2868-2875. 
30. Kan, K. W. & Ungar, F. (1974) J .  Steroid Biochem. 5,  817- 
31. Ungar, F., Kan, K. W. & McCoy, K. E. (1973) Ann. N.Y. 
32. Takagi, Y., Shikita, M. & Hall, P. F. (1975) J .  Biol. Chem. 250, 
33. Omura, T. & Sato, R. (1964) J .  Bid.  Chem. 23Y, 2370-2378. 
34. Suhara, K., Takemori, S. & Katagiri, M. (1972) Biochim. Bio- 
35. Suhara, K., Ikeda, Y., Takemori, S. & Katagiri, M. (1972) 
36. Albers, W. & Lowry. 0. H. (1955) Anal. Chcm. 27, 1829- 1831. 
Soc. Nut1 Meet. Org. 141. 
332. 
825. 
Acad. Sci. 212, 276 - 289. 
8445 - 8448. 
phys. Acta, 263, 272 - 278. 
FEBS Lett. 28, 45-57. 
37. Abraham, G .  E., Swerdloff, R., Tulchinsky, D.  & Odell, W. D. 
38. Abraham, G. E., Buster, J .  E., Kyle, F. W., Corrales, P. C. & 
39. Buster, J. E. & Abraham, G. E. (1973) Anal. Lett. 6, 147- 153. 
40. DiPietro, D. L., Brown, R. D. & Strott, C. A. (1972) J .  Clin. 
41. Manlimos, F. &Abraham, G. E. (1975) Anal. Lett. 8,403-410. 
42. Abraham, G. E., Tulchinsky, D. & Korenman, S. (1970) Bio- 
43. Wang, H.-P. & Kimura, T. (1976) J. Biol. Chem. 251, 6068- 
44. Kolattukudy, P. E. &Brown, L. (1975) Arch. Biochem. Biophys. 
45. Hanzlik, R. P., Edelman, M., Michaely, W. J. & Scott, G. 
46. Shieh, H. S., Hoard, L. G. & Nordman, C. E. (1977) Nature 
47. Craven, B. M. (1976) Nature (Lond.) 260, 727-7729, 
48. Carlisle, C. H. & Crowfoot, D. (1945) Proc. R. Soc. Lond. A 
49. Bernal, J .  D., Crowfoot, D. & Fankuchen, I. (1940) Philos. 
50. Burstein, S., Letourneux, Y., Kimball, H. L. & Gut, M. (1976) 
(1971) J .  Clin. Endocrinol. Metab. 32, 619-624. 
Teller, R. C. (1973) J. Clin. Endocrinol. Metah. 37,40-45. 
Endocrinol. Metab. 35, 729 - 735. 
chem. Med. 3, 365 - 368. 
6074. 
166, 599 - 607. 
(1976) J .  Am. Chem. Soc. Y8, 1952-1955. 
(Lond.) 267,287-289. 
184, 64 - 80. 
Trans. R .  Soc. Lond. A ,  239, 135-180. 
Steroids, 27, 361 - 383. 
B. A. Teicher, Department of Pharmacology, Yale University School of Medicine, 
333 Cedar Street, New Haven, Connecticut, U.S.A. 06510 
N. Koizumi , Department of Chemistry, The Johns Hopkins University, 
Baltimore, Maryland, U.S.A. 21218 
M. Koreeda, Department of Chemistry, University of Michigan, 
Ann Arbor, Michigan, U.S.A. 48109 
M. Shikila, National Institute of Radiological Sciences; 
9-2, 4-chome, Chiba-shi, Chiba-ken, Japan 280 
P. Talalay*, Department of Pharmacology and Experimental Therapeutics, 
Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, Maryland, U.S.A. 21205 
* To whom correspondence should be addressed. 
